Chinese Journal of Dermatology ›› 2022, Vol. 55 ›› Issue (4): 369-372.doi: 10.35541/cjd.20210898
• Reviews • Previous Articles
Luo Shuaihantian1, Long Hai1, Lu Qianjin1,2
Received:2021-12-10
Revised:2022-01-06
Online:2022-04-15
Published:2022-04-01
Contact:
Lu Qianjin
E-mail:qianlu58601@pumcderm.cams.cn
Supported by:Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2021[J]. Chinese Journal of Dermatology, 2022, 55(4): 369-372.doi:10.35541/cjd.20210898
| ［1］ | Caielli S, Athale S, Domic B, et al. Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus［J］. J Exp Med, 2016,213（5）:697⁃713. doi: 10.1084/jem.20151876. |
| ［2］ | Lood C, Blanco LP, Purmalek MM, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus⁃like disease［J］. Nat Med, 2016,22（2）:146⁃153. doi: 10.1038/nm.4027. |
| ［3］ | Caielli S, Cardenas J, de Jesus AA, et al. Erythroid mitochondrial retention triggers myeloid⁃dependent type I interferon in human SLE［J］. Cell, 2021,184（17）:4464⁃4479.e19. doi: 10.1016/j.cell.2021.07.021. |
| ［4］ | Li Y, Wang HF, Li X, et al. Disordered intestinal microbes are associated with the activity of systemic lupus erythematosus［J］. Clin Sci （Lond）, 2019,133（7）:821⁃838. doi: 10.1042/CS2018 0841. |
| ［5］ | Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to disease⁃activity associated expansions and immunity to a gut commensal［J］. Ann Rheum Dis, 2019,78（7）:947⁃956. doi: 10.1136/annrheumdis⁃2018⁃214856. |
| ［6］ | He Z, Shao T, Li H, et al. Alterations of the gut microbiome in Chinese patients with systemic lupus erythematosus［J］. Gut Pathog, 2016,8:64. doi: 10.1186/s13099⁃016⁃0146⁃9. |
| ［7］ | Chen BD, Jia XM, Xu JY, et al. An autoimmunogenic and proinflammatory profile defined by the gut microbiota of patients with untreated systemic lupus erythematosus［J］. Arthritis Rheumatol, 2021,73（2）:232⁃243. doi: 10.1002/art. 41511. |
| ［8］ | Tomofuji Y, Maeda Y, Oguro⁃Igashira E, et al. Metagenome⁃wide association study revealed disease⁃specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese［J］. Ann Rheum Dis, 2021,80（12）:1575⁃1583. doi: 10.1136/annrheumdis⁃2021⁃220687. |
| ［9］ | Lugrin J, Martinon F. The AIM2 inflammasome: sensor of pathogens and cellular perturbations［J］. Immunol Rev, 2018,281（1）:99⁃114. doi: 10.1111/imr.12618. |
| ［10］ | Yang M, Long D, Hu L, et al. AIM2 deficiency in B cells ameliorates systemic lupus erythematosus by regulating Blimp⁃1⁃Bcl⁃6 axis⁃mediated B⁃cell differentiation［J］. Signal Transduct Target Ther, 2021,6（1）:341. doi: 10.1038/s41392⁃021⁃00725⁃x. |
| ［11］ | Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron⁃dependent form of nonapoptotic cell death［J］. Cell, 2012,149（5）:1060⁃1072. doi: 10.1016/j.cell.2012.03.042. |
| ［12］ | Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4［J］. Cell, 2014,156（1⁃2）:317⁃331. doi: 10.1016/j.cell.2013.12.010. |
| ［13］ | Li P, Jiang M, Li K, et al. Glutathione peroxidase 4⁃regulated neutrophil ferroptosis induces systemic autoimmunity［J］. Nat Immunol, 2021,22（9）:1107⁃1117. doi: 10.1038/s41590⁃021⁃00993⁃3. |
| ［14］ | Yap D, Chan TM. B cell abnormalities in systemic lupus erythematosus and lupus nephritis⁃role in pathogenesis and effect of immunosuppressive treatments［J］. Int J Mol Sci, 2019,20（24）:6231. doi: 10.3390/ijms20246231. |
| ［15］ | Jenks SA, Wei C, Bugrovsky R, et al. B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus［J］. Ann Rheum Dis, 2021,80（9）:1190⁃1200. doi: 10.1136/annrheumdis⁃2021⁃220349. |
| ［16］ | Chock YP, Moulinet T, Dufrost V, et al. Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: a systematic review and meta⁃analysis［J］. Autoimmun Rev, 2019,18（11）:102395. doi: 10. 1016/j.autrev.2019.102395. |
| ［17］ | Bernardoff I, Picq A, Loiseau P, et al. Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: a systematic review and meta⁃analysis［J］. Autoimmun Rev, 2022,21（1）:102913. doi: 10.1016/j.autrev.2021.102913. |
| ［18］ | Petri M. Pregnancy and systemic lupus erythematosus［J］. Best Pract Res Clin Obstet Gynaecol, 2020,64:24⁃30. doi: 10.1016/j.bpobgyn.2019.09.002. |
| ［19］ | Braga A, Barros T, Faria R, et al. Systemic lupus erythematosus and pregnancy: a Portuguese case⁃control study［J］. Clin Rev Allergy Immunol, 2021. doi: 10.1007/s12016⁃021⁃08893⁃y. |
| ［20］ | Brudno JN, Kochenderfer JN. Recent advances in CAR T⁃cell toxicity: mechanisms, manifestations and management［J］. Blood Rev, 2019,34:45⁃55. doi: 10.1016/j.blre.2018.11.002. |
| ［21］ | Mougiakakos D, Krönke G, Völkl S, et al. CD19⁃targeted CAR T cells in refractory systemic lupus erythematosus［J］. N Engl J Med, 2021,385（6）:567⁃569. doi: 10.1056/NEJMc2107725. |
| ［22］ | Dhillon S. Telitacicept: first approval［J］. Drugs, 2021,81（14）:1671⁃1675. doi: 10.1007/s40265⁃021⁃01591⁃1. |
| ［23］ | Shi F, Xue R, Zhou X, et al. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease［J］. Immunopharmacol Immunotoxicol, 2021,43（6）:666⁃673. doi: 10.1080/08923973. 2021.1973493. |
| ［24］ | Yao X, Ren Y, Zhao Q, et al. Pharmacokinetics analysis based on target⁃mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis［J］. Eur J Pharm Sci, 2021,159:105704. doi: 10.1016/j.ejps.2021.105704. |
| ［25］ | Zhou J, Zhang Y, Li J, et al. Single⁃agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia［J］. Blood, 2010,115（9）:1697⁃1702. doi: 10.1182/blood⁃2009⁃07⁃230805. |
| ［26］ | Hamidou M, Néel A, Poupon J, et al. Safety and efficacy of low⁃dose intravenous arsenic trioxide in systemic lupus erythematosus: an open⁃label phase IIa trial （Lupsenic）［J］. Arthritis Res Ther, 2021,23（1）:70. doi: 10.1186/s13075⁃021⁃02454⁃6. |
| ［27］ | Oku K, Hamijoyo L, Kasitanon N, et al. Prevention of infective complications in systemic lupus erythematosus: a systematic literature review for the APLAR consensus statements［J］. Int J Rheum Dis, 2021,24（7）:880⁃895. doi: 10.1111/1756⁃185X. 14125. |
| [1] | Ye-Bei HU. Tranexamic acid for the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(5): 460-462. |
| [2] | . Analysis of clinicopathological features and prognosis of 163 cases of stage Ⅰ cutaneous melanoma [J]. Chinese Journal of Dermatology, 2022, 55(5): 389-394. |
| [3] | Li Wei, Yin Huibin. Heterogeneity across skin sites in atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 349-352. |
| [4] | Liu Bo, Song Xiaoting, Li Ruoyu, Zhao Zuotao. Clinical efficacy and safety of dupilumab in the treatment of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 295-298. |
| [5] | Environmental and Occupational Skin Disease Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Group on Children, Chinese Society of Dermatology. Expert consensus on clinical application of wet-wrap therapy for atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 289-294. |
| [6] | Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 0(4): 20200767-e20200767. |
| [7] | Liu Yuzhen, Zeng Rong, Zheng Nana, Duan Zhimin, Xu Haoxiang, Wu Qiuju, Lin Tong, Li Min. Effect of different incubation time of aminolevulinic acid on photodynamic inhibition of Propionibacterium acnes biofilms [J]. Chinese Journal of Dermatology, 2022, 55(3): 208-212. |
| [8] | Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022） [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195. |
| [9] | Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275. |
| [10] | Lyu Ling, Lyu Xiaoyan. Dermatomyositis with malignancy: an update [J]. Chinese Journal of Dermatology, 2022, 55(3): 276-279. |
| [11] | Li Suo, Xiang Ruiyu, Li Zhiliang, Jing Ke, Wang Yuan, Zhang Hanmei, Feng Suying. Evaluation of the value of indirect immunofluorescence on salt-split skin in the diagnosis of bullous pemphigoid [J]. Chinese Journal of Dermatology, 2022, 55(3): 235-237. |
| [12] | Ou Min, Yan Yunling, Zheng Baoqing, Wang Xiaohua. Correlations between psoriasis and obesity [J]. Chinese Journal of Dermatology, 2022, 55(2): 181-184. |
| [13] | Bao Shijie, Cheng Yang, Yan Ying, Fan Fang, Gao Tingting, Feng Xiaolan, Zheng Liang, Lei Wei, Huang Qinsi, Zhang Weiming, Zhou Xiaoyong. A comparative study of human immunoglobulin versus recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein in the treatment of toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(2): 153-156. |
| [14] | Zhang Tingting, Zhu Fengyi, Yang Mei, Zhang Ping, Xia Ping, Zhou Xiaoyong. Clinical efficacy and safety of secukinumab in the treatment of 7 cases of erythrodermic psoriasis [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210644-e20210644. |
| [15] | Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210694-e20210694. |
|
